Sarcopenia and biologic treatment in IBD
Part of Bones, joints & muscles, Digestive system clinical trials.
This study looks at how loss of muscle mass (sarcopenia) relates to the results of biologic therapy in people with inflammatory bowel disease (IBD). It aims to help understand if muscle health affects treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with inflammatory bowel disease (IBD) based on symptoms and a scope exam.
- You have received biologic therapy for your IBD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how common muscle loss (sarcopenia) is in people with inflammatory bowel disease during a flare-up, and what impact it has. By participating, you may help doctors better understand and treat muscle weakness in IBD.
This study looks at how nutrition affects people with IBD who are starting a new treatment or having surgery. Researchers want to find out if diet or body changes influence how well you recover.
This trial looks at muscle loss (called sarcopenia) in people with colon cancer to test an intervention that may help strength or recovery. If you’re age 70 or older and meet the cancer and health requirements, you may be able to take part.
This study looks at how muscle loss (sarcopenia) might affect side effects from cancer treatments. If you are starting a new cancer treatment, a CT scan before treatment can help doctors predict your risk of side effects.
This study looks at muscle loss (sarcopenia) in people with multiple sclerosis. It aims to understand what factors are linked to muscle loss, which could help improve care.
This study looks at how muscle loss (sarcopenia) affects people diagnosed with colorectal cancer before age 50. It uses CT or MRI scans taken at diagnosis to measure muscle mass and see how it relates to treatment and outcomes.
Hear when a new CT-Assessed Sarcopenia Outcomes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.